Pfizer Stock Drops 2.6% Despite Q1 Earnings Beat as Markets Rally
Pfizer’s stock slid 2.6% on May 8 even as the S&P 500 and Nasdaq Composite notched all-time highs for the sixth consecutive week. The decline followed a first-quarter earnings beat, marking Pfizer’s latest quarterly win against projected estimates.
1. Market Record Highs and Stock Reaction
On May 8, the S&P 500 and Nasdaq Composite extended winning streaks to six weeks with fresh record closes, yet Pfizer shares fell 2.6%, underperforming the broader market’s gains. The sector-wide rally, driven by cooling oil prices and artificial intelligence tailwinds, contrasted with Pfizer’s pullback.
2. First-Quarter Beat Drives Q1 Outcome
Pfizer reported a first-quarter earnings beat, surpassing consensus estimates on both revenue and earnings per share, fueled by strong vaccine and oncology sales. Despite the solid results, investor rotation into growth sectors prompted profit-taking in Pfizer shares, leading to the intraday decline.